Recent News

The latest news from the governments, medical industry and top online sources.

Francis Crick researchers target cancer cells’ ability to su…

LDHA and GOT1 enzymes successfully targeted and halted energy production in hard-to-reach cancer cells Researchers from the Francis Crick Institute have revealed how cancer cells survive after being cut off from a supply of oxygen, which could potentially help prevent cancer from becoming resistant to therapy. Published in the EMBO Journal, the study revealed that […]

Meeting highlights from the Pharmacovigilance Risk Assessmen…

EMA’s safety committee (PRAC) concluded that there was insufficient evidence to establish a causal association between the COVID-19 vaccines Comirnaty and Spikevax and cases of postmenopausal bleeding. Postmenopausal bleeding is commonly defined as vaginal bleeding occurring one year or more after the last menstrual period. Postmenopausal bleeding is always considered abnormal and can be a symptom […]

Researchers reveal two different subtypes of prostate cancer…

In the UK alone, the aggressive form of cancer affects around 52,000 men every year Researchers from the University of Oxford and the University of Manchester have revealed that prostate cancer is not just a single disease and is made up of two different evotypes – subtypes of the disease. Published in Cell Genomics, the […]

Meeting highlights from the Committee for Veterinary Medicin…

CVMP opinions on veterinary medicinal products  The Committee adopted by consensus a positive opinion for a marketing authorisation application for Alcort (hydrocortisole aceponate), from Nextmune Italy S.r.l., a new product for the alleviation of clinical signs associated with atopic dermatitis and for symptomatic treatment of inflammatory and pruritic dermatoses in dogs.  The Committee adopted by […]

Phesi’s AI-driven Trial Accelerator platform contains over 1…

The platform delivers digitalised patient data to improve clinical trials and development Phesi has announced that its artificial intelligence (AI)-driven Trial Accelerator platform has reached a critical milestone of now containing global data from more than 100 million patients. The volume will allow sponsors to access data on patients with over 4,000 indications, plan more […]

Precautionary measures to address potential risk of neurodev…

On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These measures are to address a potential increased risk of neurodevelopmental disorders in children born to men treated with valproate during the 3 months before conception. Valproate medicines are used to […]

NHS catch up campaign launched for missed MMR vaccines

Approximately one in five children will be hospitalised to treat measles The NHS has announced the launch of its new catch up campaign to get millions of children booked in for their missed measles, mumps and rubella (MMR) vaccine. The new campaign aligns with the health services efforts to protect children from becoming seriously ill […]

EMA business hours over holiday period

Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number and should only be used in the event of a potentially serious problem with a centrally authorised medicine. Source/Attributions: This news post was originally posted at […]

Wearable technology to be offered to thousands with type 1 d…

The condition affects around 270,935 people in England and 16,090 people in Wales The National Institute for Health and Care Excellence (NICE) has published final guidance announcing a five-year roll-out of a wearable technology for patients living with type 1 diabetes. The new hybrid closed loop systems have proven to be more […]

EMA Management Board: highlights of December 2023 meeting

Work programme and budget for 2024 The Board adopted EMA’s work programme for 2024, acknowledging that the Agency will continue to deliver on all its strategic priorities. EMA and the Heads of Medicines Agencies (HMA) plan to review and update the European Medicines Agencies Network Strategy looking ahead to 2028, considering the implementation of EMA’s […]